Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » ***PKTX..Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human

 - UBBFriend: Email this page to someone!    
Author Topic: ***PKTX..Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human
jackbequick
Member


Rate Member
Icon 14 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
***PKTX..Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada
Marietta, Ohio, August 27, 2020

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that Dr. James Shapiro has received approval from Health Canada and the University of Alberta Ethics Committee for the ammendments to the clinical trial protocol.

This phase of the clinical trials, based on safety data received from the initial studies in Phase 1, demonstrated the safety of the molecule and are now approved to adjust the protocols for optimal efficacy. The Company has been asked to deliver over 75-grams of the PKX-001 to the University to accommodate the ongoing clinical trial.

PKX-001 is the designation given to the lead drug product molecule of the AAGP® family. Islet cell transplants are well recognized as a viable and effective treatment for Type-1 diabetes. The PKX-001 study will treat islet cells prior to transplantation into informed patient participants. The clinical trials primary objective is the establishment of patient safety.

We are now looking at optimizing these trials for efficacy by dose escalation. The study will also be making observations related to indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trial follows extensive preclinical evaluation in experimental models (to learn more, refer to this link: Diabetes).

The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.

“We are excited to continue our trials with ProtoKinetix and their anti-aging glycopeptide product in clinical islet transplantation. Our previous studies suggested this powerful agent could improve islet engraftment and protect islets from the toxic side effects of some of the anti rejection drugs. This trial is designed to test that. We eagerly await enrolment of our next patients.” – Dr. James Shapiro

Dr. James Shapiro Bio
Dr. James Shapiro Video

About the Edmonton Protocol
Diabetes Research Institue Foundation Canada Video

To obtain additional information and updates regarding this trial please use the following link: Clinicaltrials.gov – Islet Transplantation Using PKX-001.
See the promising research of AAGP® and results to date

Posts: 193 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2019 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share